A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma

被引：4
作者：
Chen, Yuan [1 ]
Zhao, Hu [1 ]
Luo, Jing [1 ]
Liao, Youping [1 ]
Dan, Xu [2 ]
Hu, Guoyu [1 ]
Gu, Weiyue [3 ]
机构：
[1] Xiangya Med Coll CSU, Dept Hematol, Affiliated Zhuzhou Hosp, Zhuzhou, Hunan, Peoples R China
[2] YuceBio Med Technol Co Ltd, Shenzhen, Guangdong, Peoples R China
[3] Chineo Med Technol Co Ltd, Beijing, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词：
neoantigens; haploidentical T cells; adoptive T-cell therapy; peripheral T-cell lymphoma; phase I study; UP-FRONT; TRANSPLANTATION; MUTATIONS; RESPONSES; LEUKEMIA;
D O I：
10.3389/fonc.2022.944511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Peripheral T-cell lymphoma (PTCL) is a type of highly heterogeneous non-Hodgkin lymphoma with a poor prognosis and lack of effective targeted therapies. Adoptive T-cell therapy has been successfully used in the treatment of B-cell malignancies. We first used adoptive transfer of haploidentical T cells activated by patient-specific neoantigens in vitro to treat an elderly patient with refractory angioimmunoblastic T-cell lymphoma (AITL) in 2017, and the patient achieved long-term complete remission (CR). Here we report on early results from this first-in-human phase 1 clinical trial that aims to assess the safety and tolerability of neoantigen-activated haploidentical T cell therapy (NAHTC) for relapsed/refractory PTCL.
引用
收藏
页数：13
相关论文
共 50 条
  • [31] Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK®)
    Talpur, R
    Apisarnthanarax, N
    Ward, S
    Duvic, M
    LEUKEMIA & LYMPHOMA, 2002, 43 (01) : 121 - 126
  • [32] Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma
    Winsett, Frank T.
    Lewis, Daniel J.
    Duvic, Madeleine
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (09) : 757 - 760
  • [33] CAR T-cell therapy combined with autologous hematopoietic cell transplantation in patients with refractory/relapsed Burkitt Lymphoma
    Liu, Yifan
    Xiao, Gangfeng
    Liu, Yang
    Tu, Sanfang
    Xue, Bin
    Zhong, Yadi
    Zhang, Cailu
    Zhou, Lili
    Ye, Shiguang
    Lu, Yan
    Xiu, Bing
    Zhang, Wenjun
    Ding, Yi
    Fu, Jianfei
    Li, Ping
    Huang, Liang
    Luo, Xiu
    Liang, Aibin
    CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2025, 73 (01)
  • [34] Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?
    Saifi, Omran
    Kharfan-Dabaja, Mohamed A.
    Zeidan, Youssef H.
    Peterson, Jennifer
    Rule, William G.
    Lester, Scott C.
    Hoppe, Bradford S.
    INTERNATIONAL JOURNAL OF PARTICLE THERAPY, 2020, 7 (01) : 13 - 20
  • [35] Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas
    Zinzani, Pier Luigi
    Bonthapally, Vijayveer
    Huebner, Dirk
    Lutes, Richard
    Chi, Andy
    Pileri, Stefano
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 99 : 214 - 227
  • [36] A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)
    Park, Byeong-Bae
    Kim, Won Seog
    Suh, Cheolwon
    Hong, Jung Yong
    Yang, Deok-Hwan
    Lee, Won Sik
    Do, Young Rok
    Koh, Young Il
    Won, Jong-Ho
    Kim, Min Kyoung
    Jo, Jae-Cheol
    Hyun, Shin Young
    Kim, Jeong-A
    Oh, Young Ha
    Lee, Seung-Sook
    LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3251 - 3257
  • [37] Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
    Rai, Shinya
    Kim, Won Seog
    Ando, Kiyoshi
    Choi, Ilseung
    Izutsu, Koji
    Tsukamoto, Norifumi
    Yokoyama, Masahiro
    Tsukasaki, Kunihiro
    Kuroda, Junya
    Ando, Jun
    Hidaka, Michihiro
    Koh, Youngil
    Shibayama, Hirohiko
    Uchida, Toshiki
    Yang, Deok Hwan
    Ishitsuka, Kenji
    Ishizawa, Kenichi
    Kim, Jin Seok
    Lee, Hong Ghi
    Minami, Hironobu
    Eom, Hyeon Seok
    Kurosawa, Mitsutoshi
    Lee, Jae Hoon
    Lee, Jong Seok
    Lee, Won Sik
    Nagai, Hirokazu
    Shindo, Takero
    Yoon, Dok Hyun
    Yoshida, Shinichiro
    Gillings, Mireille
    Onogi, Hiroshi
    Tobinai, Kensei
    HAEMATOLOGICA, 2023, 108 (03) : 811 - 821
  • [38] Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry
    Lansigan, Frederick
    Horwitz, Steven M.
    Pinter-Brown, Lauren C.
    Rosen, Steven T.
    Pro, Barbara
    Hsi, Eric D.
    Federico, Massimo
    Gisselbrecht, Christian
    Schwartz, Marc
    Bellm, Lisa A.
    Acosta, Mark
    Shustov, Andrei R.
    Advani, Ranjana H.
    Feldman, Tatyana
    Lechowicz, Mary Jo
    Smith, Sonali M.
    Tulpule, Anil
    Craig, Michael D.
    Greer, John P.
    Kahl, Brad S.
    Leach, Joseph W.
    Morganstein, Neil
    Casulo, Carla
    Park, Steven, I
    Foss, Francine M.
    ACTA HAEMATOLOGICA, 2020, 143 (01) : 40 - 50
  • [39] Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
    Barta, Stefan K.
    Zain, Jasmine
    MacFarlane, Alexander W.
    Smith, Sonali M.
    Ruan, Jia
    Fung, Henry C.
    Tan, Carlyn R.
    Yang, Yibin
    Alpaugh, R. Katherine
    Dulaimi, Essel
    Ross, Eric A.
    Campbell, Kerry S.
    Khan, Nadia
    Siddharta, Rawat
    Fowler, Nathan H.
    Fisher, Richard, I
    Oki, Yasuhiro
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (06) : 356 - +
  • [40] THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study
    Takamatsu, Yasushi
    Suzumiya, Junji
    Utsunomiya, Atae
    Maeda, Koichi
    Matsuoka, Hitoshi
    Suzushima, Hitoshi
    Tsukada, Junichi
    Shibata, Keisuke
    Tamura, Kazuo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (05) : 391 - 397
12345